23:49:13 Europe / Stockholm

Svenska | English

Brain+

Kalender

2023-05-17	Årsstämma 2023
2023-04-28	Bokslutskommuniké 2022
2022-09-29	Kvartalsrapport 2022-Q2
2022-09-02	Extra Bolagsstämma 2022
2022-05-19	Ordinarie utdelning BRAINP 0.00 DKK
2022-05-18	Årsstämma 2022
2022-04-29	Bokslutskommuniké 2021

Beskrivning

Land	Danmark
Lista	First North Denmark
Sektor	Hälsovård
Industri	Vård & Omsorg

Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.

Filter

År

Typ

Språk

Rensa

2023-03-24 10:00:00 Brain+ A/S: Cognitive Stimulation Therapy (CST) enhances the effects of Alzheimer's disease medicine +5,16% | 0,06 MDKK

2023-03-20 08:30:00 Brain+ A/S: Brain+ expands its first sales contract, close to doubling it -2,35% | 0,07 MDKK

2023-03-14 09:30:00 Brain+ A/S: Respected dementia experts and Brain+ gets EU grant to research how to optimize digital at-home treatments for people with dementia -1,39% | 0,19 MDKK

2023-03-02 08:30:00 Brain+ A/S: New Cochrane review confirms the benefit and relevance of Cognitive Stimulation Therapy (CST) for people with dementia -0,75% | 0,08 MDKK

2023-02-21 08:35:00 Brain+ A/S: Brain+ showcases its digital dementia products at the Danish-Japanese Welfare and Health Tech Business Conference -5,41% | 0,05 MDKK

2023-02-08 08:30:12 Brain+ A/S: Successful conclusion of EU project Alzheimer's Detect & Prevent with early validation of two Brain+ DTx technologies and extra funding +8,14% | 0,57 MDKK

2023-01-26 08:30:00 Brain+ A/S: Brain+ completes Swedish research version of its dementia product with the Research Institutes of Sweden and extends the collaboration +6,05% | 0,08 MDKK

2023-01-11 13:31:54 Brain+ A/S: Results from a clinical study provide promising feasibility indications for Brain+' CCT technology for cognitive training 0,00% | 0,09 MDKK

2022-12-31 08:30:00 Brain+ A/S: Brain+ closes 2022 with the first municipal sale of its new dementia product and begins the monetization journey +11,11% | 0,06 MDKK

2022-12-28 08:30:00 Brain+ A/S: 3-year innovation project with the Danish Life Science Cluster is completed with the Brain+ CST-Therapist Companion product as the final output -2,44% | 0,03 MDKK

2022-12-16 08:30:00 Brain+ A/S: Brain+ begins commercial pilot with volunteers from the DaneAge Association +4,44% | 0,02 MDKK

2022-12-14 08:45:00 Brain+ A/S: Brain+ completes the implementation of an ISO 13485 Quality Management System for Medical Devices -0,51% | 0,02 MDKK

2022-12-09 11:00:00 Brain+ A/S: A new WHO report points to Cognitive Stimulation Therapy (CST) and digital solutions as means to help solve the global dementia burden +9,09% | 0,04 MDKK

2022-10-31 19:19:12 Warrants of Series TO1 expected subscribed to approximately 82% of the offered amount and Brain+ A/S to receive approximately DKK 6,4m before issuing costs +14,23% | 0,16 MDKK

2022-10-27 10:30:00 Brain+ A/S: Brain+ adds new clinical and development competencies to accelerate and support market access of its digital dementia product portfolio +2,18% | 0,03 MDKK

2022-10-24 13:40:28 Brain+ A/S: Investor Update: Exercise via Nordnet of TO1 warrants possible until October 27[th] 2022 0,00% | 0,27 MDKK

2022-10-24 08:30:26 Brain+ A/S: Brain+ further advances its first digital dementia product, Cognitive Stimulation Therapy (CST)-Therapist Companion 0,00% | 0,27 MDKK

2022-10-19 08:00:00 Brain+ A/S: Brain+ begins early activity and brand building in the US 0,00% | 0,10 MDKK

2022-10-17 14:31:28 Brain+ CEO and Board members exercise IPO warrants to subscribe for new shares in Brain+ A/S for DKK 0.5m +4,91% | 0,13 MDKK

2022-10-14 18:20:31 Brain+ A/S: Brain+ announces details on the exercise of IPO warrants to subscribe for new shares, including the exercise price for the warrants +4,91% | 0,13 MDKK

2022-10-12 08:00:00 Brain+ A/S: Brain+ meets the first milestone in its pharma partnership with Rox Health (Roche Germany) on its digital Cognitive Stimulation Therapy products +2,71% | 0,13 MDKK

2022-10-11 08:36:14 Swedish-based Analyst Group releases first commissioned equity research of Brain+ A/S and base case values the company at DKK 4.1 per share -7,14% | 0,15 MDKK

2022-10-11 08:15:32 Brain+ A/S: Brain+ informs of new IR initiatives, including initiation of commissioned research, and invites to its first live Investor Update -7,14% | 0,15 MDKK

2022-10-07 14:45:00 Brain+ A/S: The pricing period for Brain+'s warrants of series TO 1 is underway -9,84% | 0,27 MDKK

2022-10-07 11:00:00 Brain+ A/S: World Alzheimer's Report 2022 highlights Cognitive Stimulation Therapy -9,84% | 0,27 MDKK

2022-09-29 10:02:33 Brain+ A/S: Summary from H1 2022 report: Brain+ (BRAINP) on track for accelerated first dementia product launches in Denmark and Germany in 2022 and 2023 -3,45% | 0,04 MDKK

2022-09-29 10:00:48 Brain+ A/S: Interim Report for the Period 1. January 2022 - 30. June 2022 -3,45% | 0,04 MDKK

2022-09-28 09:25:42 Brain+ A/S: Brain+ partners with German medical distributor - and advances launch of its first CST dementia product in Germany to Q2 2023 +0,35% | 0,17 MDKK

2022-09-26 08:46:36 Brain+ A/S: BioStock Investor Meeting: Interview with Brain+ +0,36% | 0,15 MDKK

2022-09-26 08:46:36 Brain+ A/S: BioStock Investor Meeting: Intervju med Brain+ +0,36% | 0,15 MDKK

2022-09-21 08:56:15 Brain+ A/S: BioStock Investor Meeting: Brain+ presenterar -2,76% | 0,07 MDKK

2022-09-05 10:00:18 Brain+ A/S appoints Anders Härfstrand as new Chairman of the Board -4,39% | 0,12 MDKK

2022-09-02 11:15:23 Brain+ A/S: Brain+ announces results of Extraordinary General Meeting of Shareholders 0,00% | 0,04 MDKK

2022-08-26 12:01:53 Brain+ A/S: Brain+' new digital product for dementia, "CST-Therapist Companion" is ready for commercial launch in Denmark in Q4 2022 - one year ahead of plan +8,00% | 0,11 MDKK

2022-08-08 08:30:00 Brain+ A/S intends to add three international life science profiles as new board members in a strategic move ahead of its near-term commercial launch +2,44% | 0,01 MDKK

2022-08-08 08:30:00 Notice of Extraordinary General Meeting of Brain+ A/S +2,44% | 0,01 MDKK

2022-08-02 08:30:00 Brain+ A/S: Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia -0,46% | 0,00 MDKK

2022-07-12 08:30:00 Brain+ A/S: Common Nordic digital health evaluation framework launched 0,00% | 0,01 MDKK

2022-06-24 08:30:00 Brain+ A/S: Germany opens the DiPA reimbursement pathway to support the adoption of digital health applications, underpinning the value of the #1 target market for Brain+' first commercial dementia product, CST -7,73% | 0,02 MDKK

2022-05-25 08:30:00 Brain+ A/S: 1m SEK FORTE grant project to map state of the art digital interventions for dementia beings, helping Brain+ to strengthen patient and caregiver compliance for product development +2,22% | 0,02 MDKK

2022-05-18 15:05:03 Minutes of the Annual General Meeting 2022 in Brain+ A/S +1,99% | 0,00 MDKK

2022-05-03 22:14:25 Notice of Annual General Meeting of Brain+ A/S and Change to the Board of Directors 0,00% | 0,00 MDKK

2022-04-29 10:41:51 Brain+ A/S: Summary from Annual Report 2021: Brain+ (BRAINP) is ahead of its IPO plan -0,78% | 0,04 MDKK

2022-04-29 10:40:14 Annual Report 2021 for Brain+ A/S -0,78% | 0,04 MDKK

2022-04-20 08:30:00 Brain+ A/S: Brain+ CTO unfolds the Company's Technology Platform Strategy +5,83% | 0,03 MDKK

2022-03-25 08:00:00 Brain+ A/S: Brain+ selected as `digital showcase for Denmark' by Digital Hub Denmark +4,00% | 0,04 MDKK

2022-03-16 08:00:00 Brain+ A/S: The Danish Foreign Ministry to promote Brain+ into elderly care homes in Germany - Europe's largest Alzheimer's market +10,24% | 0,09 MDKK

2022-03-15 08:30:00 Brain+ A/S: Brain+ and Biogen preparing for commercialization in Germany, the #1 EU market for digital therapeutics +8,55% | 0,04 MDKK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Brain+

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden